RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Patient-reported outcomes from two global multicenter clinical trials of children and adults with tropomyosin receptor kinase (TRK) fusion cancer receiving larotrectinib
Kummar, S., Mascarenhas, L., Geoerger, B., Turpin, B., Cox, MC., Yu, S., Nanda, S., Hiemeyer, F., Keating, KN., Chirila, C., Gnanasakthy, A., Davenport, E. K., Hong, D., & Drilon, AE. (2019). Patient-reported outcomes from two global multicenter clinical trials of children and adults with tropomyosin receptor kinase (TRK) fusion cancer receiving larotrectinib. Journal of Clinical Oncology, 37(2019), 6602.